F. She

Effects of CYP3A Modulators on the Pharmacokinetics of Naloxegol

Diansong Zhou, K. Bui, N. Al-Huniti, 2016, Journal of clinical pharmacology.

The effects of renal impairment on the pharmacokinetics, safety, and tolerability of naloxegol

K. Bui, M. Sostek, F. She, 2014, Journal of clinical pharmacology.

P.4.e.005 Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the treatment of GAD

H. Eriksson, C. Merideth, F. She, 2008, European Neuropsychopharmacology.

The effects of mild or moderate hepatic impairment on the pharmacokinetics, safety, and tolerability of naloxegol

K. Bui, M. Sostek, F. She, 2014, Journal of clinical pharmacology.

The effect of quinidine, a strong P‐glycoprotein inhibitor, on the pharmacokinetics and central nervous system distribution of naloxegol

Diansong Zhou, K. Bui, N. Al-Huniti, 2016, Journal of clinical pharmacology.

Absorption, distribution, metabolism, and excretion of [14C]-labeled naloxegol in healthy subjects

M. Hutchison, K. Bui, M. Sostek, 2015, International journal of clinical pharmacology and therapeutics.

Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in patients with generalized anxiety disorder and a history of inadequate treatment response: a randomized, double-blind study.

F. She, ArifUllah Khan, S. Pathak, 2013, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder: a randomized, placebo controlled and active-controlled study

H. Eriksson, A. Cutler, C. Merideth, 2012, International clinical psychopharmacology.

Double‐blind, randomized study of extended release quetiapine fumarate (quetiapine XR) monotherapy in older patients with generalized anxiety disorder

H. Eriksson, C. Datto, F. She, 2013, International journal of geriatric psychiatry.